POINT Biopharma Global Inc (PNT)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Joe McCann
Employees:
70
4850 WEST 78TH STREET, INDIANAPOLIS, IN, 46268
(647) 401-2182

POINT Biopharma Global Inc. focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioliand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the. treatment of non-metastatic. castration sensitive prostate cancer, which is under study.

Data derived from most recent annual or quarterly report
Market Cap 1.46 Billion Shares Outstanding105.766 Million Avg 30-day Volume 2.869 Million
P/E Ratio9.8431 Dividend Yield0.0 EPS-0.23
Price to Revenue3.9761 Debt to Equity0.0339 EBITDA106.004 Million
Price to Book Value2.1407 Operating Margin0.0 Enterprise Value915.725 Million
Current Ratio EPS Growth2.305 Quick Ratio
1 Yr BETA 0.084 52-week High/Low 13.9 / 6.39 Profit Margin40.395
Operating Cash Flow Growth309.2573 Free Cash Flow to Firm (FCFF) TTM -152.875 Million Free Cash Flow to Equity (FCFE) TTM65.876 Million
Altman Z-Score
View SEC Filings from PNT instead.

View recent insider trading info

POINT Biopharma Global Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding PNT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PNT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-11-07 by MCCANN JOE A.
  • 4: filed on 2023-11-02 by FLESHNER NEIL E.
  • 4: filed on 2023-06-05 by HOGUE GERALD L.
  • 4: filed on 2023-06-05 by GOODMAN JONATHAN R.
  • 4: filed on 2023-06-05 by MARGOLIN YAEL
  • 4: filed on 2023-03-30 by SILBER ALLAN C
  • 4: filed on 2023-03-30 by MCCANN JOE A.
  • 4: filed on 2023-03-30 by KELLY JUSTYNA
  • 4: filed on 2023-03-30 by JENSEN JESSICA D.
  • 4: filed on 2023-03-30 by FLESHNER NEIL E.

    • Events (8k)

  • 8-K: filed on 2023-10-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-03:
    Item 4.01: Changes in Registrant's Certifying Accountant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-06-05:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-02-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-14:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-13:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-12:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-06:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MCCANN JOE A. CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 3,496,313 2023-11-06 2

    SILBER ALLAN C EXECUTIVE CHAIRMAN

    • Officer
    • Director
    		 8,727,975 2023-11-03 2

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BVF I GP LLC

    BIOTECHNOLOGY VALUE FUND II LP

    BVF II GP LLC

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF GP HOLDINGS LLC

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		17,161,278 2023-11-02 1

    FLESHNER NEIL E. CHIEF MEDICAL OFFICER

    • Officer
    • Director
    		 3,006,574 2023-10-31 2

    MARTELL BRIDGET A

    • Director
    		 0 2023-06-13 2

    LUBNER DAVID CHARLES

    • Director
    		 0 2023-06-01 1

    MALIK RAJESH

    • Director
    		 0 2023-06-01 1

    GOODMAN JONATHAN R.

    • Director
    		 0 2023-06-01 1

    MARGOLIN YAEL

    • Director
    		 0 2023-06-01 1

    HOGUE GERALD L.

    • Director
    		 0 2023-06-01 2

    DEMERS WILLIAM L. CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-03-28 1

    JENSEN JESSICA D. EVP CLINICAL DEVELOPMENT

    • Officer
    		 0 2023-03-28 1

    KELLY JUSTYNA CHIEF OPERATING OFFICER

    • Officer
    		 0 2023-03-28 1

    GOTTLIEB MICHAEL M. CHIEF COMMERCIAL OFFICER

    • Officer
    		 48,000 2021-07-06 0

    GILMOUR MARGARET E.

    • Director
    		 25,000 2021-07-06 0

    RA CAPITAL MANAGEMENT, L.P.

    RA CAPITAL HEALTHCARE FUND LP

    SHAH RAJEEV M.

    • Director
    		 1,098,318 2021-06-29 0

    KOLCHINSKY PETER CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,098,318 2021-06-29 0

    GRAY MICHAEL

    • Director
    		 0 2020-07-07 0

    GRAU DANIEL

    • Director
    		 0 2020-07-07 0

    THERAPEUTICS ACQUISITION HOLDINGS LLC

    • 10% Owner
    		 0 2020-07-07 0

    HAMMOND MATTHEW CHIEF FINANCIAL OFFICER

    • Officer
    • Director
    		 0 2020-07-07 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    MCCANN JOE A. - Director - Officer CHIEF EXECUTIVE OFFICER personal holding company

    		2023-11-07 18:33:24 -0500 2023-11-06 G 120,000 d 3,494,153 indirect 1.3825 2.9186 2.9186 6 0.0 1

    SILBER ALLAN C - Director - Officer EXECUTIVE CHAIRMAN trustee

    		2023-11-07 18:31:49 -0500 2023-11-03 G 500,000 d 38,087 indirect 1.3825 2.9186 2.9186 6 0.0 1

    FLESHNER NEIL E. - Director - Officer CHIEF MEDICAL OFFICER

    		2023-11-02 18:30:24 -0400 2023-10-31 G 250,000 d 2,773,045 direct 2.2745 2.902 3.5294 5 0.0 1

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 22:15:04 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 21:45:03 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 21:15:04 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 20:45:04 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 20:15:04 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 19:45:03 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 19:15:04 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 18:45:03 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 18:15:03 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 17:45:04 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 17:15:04 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 16:45:04 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 16:15:04 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 15:45:03 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 15:15:03 UTC 4.7052 0.6148 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 14:45:04 UTC 4.7045 0.6155 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 14:15:04 UTC 4.7045 0.6155 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 13:45:04 UTC 4.7045 0.6155 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 13:15:03 UTC 4.7045 0.6155 1900000
    POINT BIOPHARMA GLOBAL INC PNT 2023-11-28 12:45:04 UTC 4.7045 0.6155 1900000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments